Your search returned 12 results.

Results
	1.	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. MedStar authors: Swain, Sandra M PMID: 25332249 Year: 2014 Citation: Journal of Clinical Oncology. 32(33):3744-52, 2014 Nov 20. Institution: Washington Cancer Institute Medline publication type: Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Colon-Otero G, Davidson NE, Geyer CE Jr, Gralow J, Jeong JH, Mamounas E, Martino S, Perez EA, Rastogi P, Romond EH, Sledge G, Suman VJ, Swain SM, Winer EP, Wolmark N, Zujewski JA DOI: http://dx.doi.org/10.1200/JCO.2014.55.5730 Add to cart (remove)
	2.	Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24685829 Year: 2014 Citation: Annals of Oncology. 25(6):1116-21, 2014 Jun. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Cortes J, Im YH, Lee LF, Miles D, Quah C, Swain SM DOI: http://dx.doi.org/10.1093/annonc/mdu133 Add to cart (remove)
	3.	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors: Swain, Sandra M PMID: 24129974 Year: 2013 Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM DOI: http://dx.doi.org/10.1007/s10549-013-2710-z Add to cart (remove)
	4.	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. [Review] MedStar authors: Swain, Sandra M PMID: 24529560 Year: 2014 Citation: Lancet. 384(9938):164-72, 2014 Jul 12. Medline publication type: Journal Article Meta-Analysis Research Support, U.S. Gov't, P.H.S. Review Form of publication: Journal Article All authors: Baselga J, Bergh J, Blohmer J, Blumenthal G, Bogaerts J, Bonnefoi H, Cameron D, Cortazar P, Costantino JP, Ditsch N, Eidtmann H, Eiermann W, Fasching PA, Gerber B, Geyer CE Jr, Gianni L, Justice R, Loibl S, Mamounas EP, Mehta K, Paik S, Pazdur R, Perou C, Piccart M, Prowell T, Rastogi P, Semiglazov V, Slaets L, Sridhara R, Swain SM, Tang S, Untch M, Valagussa P, von Minckwitz G, Wickerham DL, Wolmark N, Zhang L DOI: http://dx.doi.org/10.1016/S0140-6736(13)62422-8 Add to cart (remove)
	5.	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 25693012 Year: 2015 Citation: New England Journal of Medicine. 372(8):724-34, 2015 Feb 19. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1056/NEJMoa1413513 Add to cart (remove)
	6.	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24869931 Year: 2014 Citation: Oncologist. 19(7):693-701, 2014 Jul. Institution: Washington Cancer Institute Form of publication: Journal Article All authors: Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2014-0033 Add to cart (remove)
	7.	HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens. MedStar authors: Swain, Sandra M PMID: 27692565 Year: 2017 Citation: Clinical Breast Cancer. 17(1):76-78, 2017 Feb Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Gao JJ, Pohlmann PR, Swain SM, Tan M DOI: https://dx.doi.org/10.1016/j.clbc.2016.08.005 Add to cart (remove)
	8.	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors: Swain, Sandra M PMID: 23602601 Year: 2013 Citation: Lancet Oncology. 14(6):461-71, 2013 May. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1016/S1470-2045(13)70130-X Add to cart (remove)
	9.	Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors: Swain, Sandra M PMID: 23969513 Year: 2013 Citation: Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Journal Article Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J DOI: http://dx.doi.org/10.1097/CAD.0000000000000016 Add to cart (remove)
	10.	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors: Swain, Sandra M PMID: 22276821 Year: 2012 Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26. Institution: Washington Cancer Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Form of publication: Journal Article All authors: Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1056/NEJMoa1111097 Add to cart (remove)
	11.	SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. MedStar authors: Asch, Federico M Barac, Ana Lynce, Filipa Swain, Sandra M PMID: 28314836 Year: 2017 Citation: Oncologist. 22(5):518-525, 2017 May Institution: MedStar Heart & Vascular Institute Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Asch FM, Barac A, Dang C, Isaacs C, Lynce F, Smith KL, Swain SM, Tan MT DOI: https://dx.doi.org/10.1634/theoncologist.2016-0412 Add to cart (remove)
	12.	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors: Asch, Federico M Barac, Ana Cunningham, A Gallagher, Christopher Hofmeyer, Mark Srichai, M B Swain, Sandra M PMID: 30852761 Year: 2019 Citation: Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun. Institution: MedStar Health MedStar Health Research Institute MedStar Heart & Vascular Institute Washington Cancer Institute Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF DOI: https://dx.doi.org/10.1007/s10549-019-05191-2 Add to cart (remove)

Powered by Koha